With $270M in new funds, Shankar Ramaswamy looks beyond Roivant in scaling his gene therapy 'consolidated engine'
Shankar Ramaswamy doesn’t intend to repeat the Roivant playbook that his brother started eight years ago. Instead, he wants to consolidate the gene therapy process and be the go-to shop in a field that has ridden a rocky road for many years.
Amid a bear market, he and his 160-employee biotech have reeled in a $270 million Series C.
“Notwithstanding the broader market conditions, I think we are building a very different type of company that I think resembles what we’ve seen in other modalities, whether it’s in mRNA, or monoclonal antibodies, or RNAi technologies,” Ramaswamy told Endpoints News.